Syndax Pharmaceuticals (NasdaqGS:SNDX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsClara Dong - VP of Equity Research in BiotechnologyCorinne Johnson - Managing DirectorDavid Dai - DirectorJason Zemansky - VP of Equity ResearchJosh Bowen - DirectorKeith Goldan - CFOMichael Metzger - CEONick Botwood - Head of R&D and Chief Medical OfficerPriyanka Grover - VP of Biotechnology Equity ResearchSharon Klahre - Head of Investor RelationsStephen Willey - Managing DirectorSteve Closter - ...

Syndax Pharmaceuticals (NasdaqGS:SNDX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsClara Dong - VP of Equity Research in BiotechnologyCorinne Johnson - Managing DirectorDavid Dai - DirectorJason Zemansky - VP of Equity ResearchJosh Bowen - DirectorKeith Goldan - CFOMichael Metzger - CEONick Botwood - Head of R&D and Chief Medical OfficerPriyanka Grover - VP of Biotechnology Equity ResearchSharon Klahre - Head of Investor RelationsStephen Willey - Managing DirectorSteve Closter - ...

Syndax Pharmaceuticals (NasdaqGS:SNDX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker10Good day, everyone. Welcome to the Syndax fourth quarter 2025 earnings conference call. Today's call is being recorded. If you would like to ask a question following the company's prepared remarks, please press star five during the call. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.Speaker13Thank you, operator. Welcome, and thank you a ...

Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events, progress, timing or circumstances) are intended to identify forward-looking statements. All statements other than statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 32-0162505 (State or Other J ...

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – Exhibit 99.1 NEW YORK, NY, February 26, 2026 (GLOBE NEWSWIRE) – Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "We solidified our leaders ...

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2 IPF trial of axatilimab; topline data expected in 4Q26 – – Company to host a conference call to ...

Core Viewpoint - Syndax Pharmaceuticals will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call and live audio webcast to discuss the results and provide a business update [1]. Group 1: Financial Results Announcement - The earnings release is scheduled for Thursday, February 26, 2026 [1]. - A conference call and live audio webcast will take place at 4:30 p.m. ET on the same day [1]. Group 2: Access Information - The live audio webcast and accompanying slides can be accessed through the Events & Presentations page in the Investors section of the Company's website [2]. - Conference ID for the call is Syndax4Q25, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800 [2]. - A replay of the conference call will be available approximately 24 hours after the event and will remain accessible for 90 days [2]. Group 3: Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3]. - Key products in the pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3]. - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3].

Core Insights - Syndax Pharmaceuticals is experiencing significant growth driven by its products Revuforj and Niktimvo, with a strong commercial performance expected to continue into 2026 [4][7]. Product Performance - Revuforj has shown a 38% growth in the fourth quarter, attributed to its use in KMT2A-rearranged acute myeloid leukemia (AML) and new momentum in NPM1-mutant AML following recent guideline inclusion and approval [2][3]. - Niktimvo has generated $152 million in net sales within its first 11 months on the market for chronic graft-versus-host disease (GVHD), indicating strong uptake [3][7]. - The company anticipates Revuforj's average treatment duration to increase from 4-6 months to 6-12 months as maintenance adoption rises from 35-40% to an expected 70-80% [6][12]. Market Opportunities - The U.S. market for Niktimvo in the third-line-plus setting is estimated at approximately 6,500 patients, with a frontline opportunity of around 17,000 patients, suggesting a potential approach to $1 billion in sales [5][15]. - Syndax expects to dominate the market share in NPM1-mutant AML, although it is currently too early to quantify [8]. Financial Outlook - The company has guided flat operating expenses at $400 million for 2026 and is fully funded, indicating no immediate need for additional cash [23]. - Syndax's collaboration with Incyte involves a 50/50 profit split, with expectations that 25-30% of Incyte's reported net sales will contribute to Syndax's revenue [16][17]. Clinical Development - Syndax is advancing a Phase II trial in idiopathic pulmonary fibrosis (IPF) with results expected in the second half of 2026, and a Phase II trial combining Niktimvo with Jakafi is anticipated to read out in early 2027 [18][20]. - The company is also exploring myelofibrosis treatment options, with preclinical work showing promising results [13][14].

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now. On February 3, Bank of America analyst Jason Zemansky raised the firm’s price target on Syndax to $28 from $27 and kept a Buy rating. Zemansky noted that due to the volume of pre-announcements, upcoming Q4 2025 earnings may not have the same impact as in prior years. Earlier on January 7, Syndax Pharmaceuticals partnered with the World Orphan Drug Alliance to launch a Managed Access Program for Revuforj (revu ...